SPL 0.00% 9.9¢ starpharma holdings limited

;) potential interested partners looking at us this year from...

  1. 15,733 Posts.
    lightbulb Created with Sketch. 5758
    potential interested partners looking at us this year from ASCO will need to conduct their thorough due diligence and scientific validation.


    1. What do you think the “several” potential partners have been doing behind NDA’s over the last few years ?  …. and of course you do realise the trials were open label so between what DEP data has been released publicly in the last 3 years and this additional open label data potential partners would have seen why wouldn’t they be jumping on a DEP license agreement if the “science is so good” ?


    2. By doing “their own thorough Scientific Validation” would involve further preclinical studies and trials that will take years and of course what do you think all the supposed partners who signed research agreements with Starpharma have been doing for the last 3-9 years … two of which (AstraZeneca and Chase) as advised by the new CEO in the Webinar are now doing nothing in this regard ?


    3.  You’re suggesting in one part of your post that the “DEP tech has only now been proven” but in this comment above later in the post you claim any potential partners will want to do their own ‘scientific validation’ ? In that case, it sounds like Starpharma have validated nothing then by the looks after all the years of trials - all the phase 2 trial data either scientifically validates the DEP tech or it doesn’t ? It’s one or the other ?   


    4. You still haven’t provided the names of any drugs featured in the 2023 ASCO conference that commanded the sorts of license deal premiums many have posted on here that our DEP drugs are supposedly worth so perhaps the ASCO conference isn’t as “exclusive” as you made it out to be ?


    Overall it sounds like the company is back at the drawing board once again (the recent Medicxi deal also supports that narrative ) and sadly many on here seem just fine with that as they dismiss the years of touting of supposed “well advanced DEP licensing discussions” from Starpharma that appear at this stage to have amounted to diddly squat ? Me not so much and that is why as I advised earlier in the week, I am making my own enquiries as to how to hold this mob accountable.



    Enjoy your day …
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
9.9¢
Change
0.000(0.00%)
Mkt cap ! $41.39M
Open High Low Value Volume
9.9¢ 10.3¢ 9.9¢ $278.7K 2.781M

Buyers (Bids)

No. Vol. Price($)
1 73885 9.9¢
 

Sellers (Offers)

Price($) Vol. No.
10.0¢ 6037 1
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.